HOME >> MEDICINE >> NEWS
Use of statins may prevent breast cancer, say University of Pittsburgh researchers

PITTSBURGH, Oct. 16 Cholesterol-lowering medications may help to prevent breast cancer in older women, according to study findings published by University of Pittsburgh researchers in the October issue of the Journal of Women's Health.

"While scientists have known for years that cholesterol inhibition serves to inhibit tumor cell growth, our analysis is one of the first to look exclusively at the relationship between lipid-lowering medications and the development of breast cancer, and our findings are dramatically positive," said study author and lead investigator Jane Cauley, Dr.P.H., professor of epidemiology at the University of Pittsburgh Graduate School of Public Health.

The Pittsburgh-led study found that older women who took statins and non-statin lipid-lowering drugs experienced a 60 to 70 percent reduction in their risk of breast cancer over approximately seven years.

Researchers reviewed data on 7,528 white women age 65 years and older who participated in the Study of Osteoporotic Fractures at sites in Pittsburgh, Baltimore, Minneapolis and Portland, and followed them for seven years.

A total of 234 (3.3%) cases of breast cancer were reported among the 6,952 participants who reported no use of lipid-lowering drugs; six cases (2.1%) among the 284 women who used statins; and four cases (1.3%) among the 292 who used nonstatin lipid-lowering drugs. The combined group of lipid-lowering drug users had a 68 percent reduction in the risk of breast cancer.

Investigators adjusted for body mass index and other risk factors for breast cancer such as the age at menarche, age at first birth, parity, physical activity and alcohol consumption. The results were essentially the same in all cases.

"There is a significant difference in the percentage of breast cancer events between women who used lipid-lowering drugs and those who did not, and these findings have important public health implications given the widespread use
'"/>

Contact: Kathryn Duda
DudaK@upmc.edu
412-624-2607
University of Pittsburgh Medical Center
16-Oct-2003


Page: 1 2

Related medicine news :

1. Hepatotoxicity and statins
2. Jefferson scientists help explain statins effects in Alzheimers disease
3. Jefferson scientists uncover new evidence to help explain statins effects in Alzheimers disease
4. CRESTOR leads in 1st international prospective study of statins in the metabolic syndrome
5. OTC statins: A bad decision for public health
6. ESC highlights need for screening and global risk management as statins move over the counter in UK
7. ACP guidelines: Many diabetics should be taking statins
8. Patients should be allowed to pay for statins
9. Genetic bar codes predict effect of statins
10. Stopping statins may cause rebound that triples risk of death
11. Not enough evidence that multivitamins prevent infections in the elderly

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/17/2017)... ... February 17, 2017 , ... ... services, announced today that Karen Pilley has been promoted to Chief Executive Officer. ... today’s shifting healthcare paradigm – a shift that demands the transition from pay-for-service ...
(Date:2/17/2017)... ... February 17, 2017 , ... Like most hospitals across the nation, Onslow Memorial ... by the Hospital Readmission Reduction Program (HRRP), the return of a patient to the ... across the nation. While many providers are struggling to leverage limited resources and technology, ...
(Date:2/16/2017)... ... February 17, 2017 , ... ... took over 10 years of research, development and clinical trials, the founder of ... is a patented compound of FDA approved ingredients that when infused into alcohol, ...
(Date:2/16/2017)... ... February 16, 2017 , ... ... and superiority in patient care, NWH has achieved Magnet® recognition for ... Tuesday, January 31, 2017. The American Nurses Credentialing Center’s Magnet Recognition Program® distinguishes ...
(Date:2/16/2017)... ... February 16, 2017 , ... A February 6 ... as fat freezing or CoolSculpting, noting that some 425,000 procedures were performed with the ... that the clinic is, in fact, seeing a great deal of interest from area ...
Breaking Medicine News(10 mins):
(Date:2/17/2017)... YORK , Feb. 17, 2017  Noble Capital ... on ESSA Pharma Inc. (Nasdaq: EPIX ). ... Research, Kumar Raja , PhD. ESSA ... for castration resistant prostate cancer (CRPC). Its lead compound ... blocks the amino-terminal domain of the androgen receptor, thereby ...
(Date:2/16/2017)... , Feb. 16, 2017 The global ... USD 7.88 billion by 2021 from USD 5.49 billion ... On the basis of type, the preparative and ... preparative chromatography. In 2016, the process chromatography segment is ... global preparative and process chromatography. Growth in this segment ...
(Date:2/16/2017)... , Feb. 16, 2017  AcelRx Pharmaceuticals, Inc. ... company focused on the development and commercialization of ... pain, announced that Vincent J. Angotti ... member of the company,s board of directors, effective ... two decades of experience leading executive and commercial ...
Breaking Medicine Technology:
Cached News: